NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM

NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e. TEG002, in a dose escalation and expansion study in relapsed/refractory Multiple Myeloma patients.

Sponsor

Gadeta B.V.

---

ClinicalTrials.gov Identifier: NCT04688853

Official Title: A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients

First Posted: December 30, 2020

Click here for details on ClinicalTrials.gov

---

TEG002

---

Location

United States, Massachusetts